HK1059038A1 - Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression - Google Patents

Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression

Info

Publication number
HK1059038A1
HK1059038A1 HK04101904A HK04101904A HK1059038A1 HK 1059038 A1 HK1059038 A1 HK 1059038A1 HK 04101904 A HK04101904 A HK 04101904A HK 04101904 A HK04101904 A HK 04101904A HK 1059038 A1 HK1059038 A1 HK 1059038A1
Authority
HK
Hong Kong
Prior art keywords
integrin expression
angionegesis
inhibition
inhibitor mediated
examining effect
Prior art date
Application number
HK04101904A
Other languages
English (en)
Inventor
Naoto Ono
Taro Senba
Naoko Hata
Yasuhiro Funahashi
Toshiaki Wakabayashi
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of HK1059038A1 publication Critical patent/HK1059038A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK04101904A 2001-02-21 2004-03-16 Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression HK1059038A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001044646 2001-02-21
PCT/JP2002/001562 WO2002066073A1 (fr) 2001-02-21 2002-02-21 Procede servant a analyser l'effet d'un inhibiteur d'angiogenese medie par l'inhibition de l'expression de l'integrine

Publications (1)

Publication Number Publication Date
HK1059038A1 true HK1059038A1 (en) 2004-06-18

Family

ID=18906601

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04101904A HK1059038A1 (en) 2001-02-21 2004-03-16 Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression
HK07106835A HK1099363A1 (en) 2001-02-21 2007-06-26 Method for testing effect of angiogenesis inhibitor via integrin expression inhibition

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK07106835A HK1099363A1 (en) 2001-02-21 2007-06-26 Method for testing effect of angiogenesis inhibitor via integrin expression inhibition

Country Status (12)

Country Link
US (1) US7122318B2 (fr)
EP (2) EP1362601B8 (fr)
JP (1) JP4255285B2 (fr)
KR (1) KR20030080013A (fr)
CN (2) CN101025419A (fr)
AT (2) ATE350660T1 (fr)
AU (1) AU2002233677B2 (fr)
CA (1) CA2438427C (fr)
DE (2) DE60229676D1 (fr)
ES (2) ES2280502T3 (fr)
HK (2) HK1059038A1 (fr)
WO (1) WO2002066073A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002233677B2 (en) 2001-02-21 2005-01-06 Eisai R&D Management Co., Ltd. Method of examining effect of angiogenesis inhibitor mediated by the inhibition of integrin expression
EP1430894A4 (fr) * 2001-09-05 2007-12-12 Eisai R&D Man Co Ltd Inhibiteur d'activation lymphocytaire et remede pour maladie auto-immune
WO2005090297A1 (fr) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Derives sulfonamides
WO2006090927A1 (fr) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Action orexigenique d'un compose de sulfonamide
PL1893612T3 (pl) 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
WO2007086605A1 (fr) * 2006-01-27 2007-08-02 Eisai R & D Management Co., Ltd. Procédé de prédiction de l'effet d'un composé de sulfonamide
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
EP3873884A1 (fr) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Dérivés de quinoléine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
WO2020092401A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOSÉS POUR INHIBITION DE L'INTÉGRINE ALPHA 4β7
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2128648C1 (ru) * 1993-09-10 1999-04-10 Эйсай Ко. Лтд. Производные сульфонамида, способы их получения, фармацевтическая композиция и способ лечения
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
EP0889876B1 (fr) 1996-03-29 2001-07-25 G.D. SEARLE & CO. Derives meta-substitues du sulphonamide de phenylene
SK163598A3 (en) * 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
WO1998044797A1 (fr) * 1997-04-07 1998-10-15 Merck & Co., Inc. Procede de traitement du cancer
US6096707A (en) 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
JP2000247949A (ja) 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
JP4039856B2 (ja) 2000-02-03 2008-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 インテグリン発現阻害剤
AU2002233677B2 (en) 2001-02-21 2005-01-06 Eisai R&D Management Co., Ltd. Method of examining effect of angiogenesis inhibitor mediated by the inhibition of integrin expression

Also Published As

Publication number Publication date
EP1742052A1 (fr) 2007-01-10
JPWO2002066073A1 (ja) 2004-06-17
DE60229676D1 (de) 2008-12-11
ES2317368T3 (es) 2009-04-16
EP1362601A4 (fr) 2005-07-06
DE60217300D1 (de) 2007-02-15
CA2438427A1 (fr) 2002-08-29
ATE412895T1 (de) 2008-11-15
ES2280502T3 (es) 2007-09-16
HK1099363A1 (en) 2007-08-10
ATE350660T1 (de) 2007-01-15
EP1362601B8 (fr) 2007-02-28
US7122318B2 (en) 2006-10-17
CN101025419A (zh) 2007-08-29
CN1620313A (zh) 2005-05-25
CA2438427C (fr) 2011-04-12
EP1362601A1 (fr) 2003-11-19
WO2002066073A1 (fr) 2002-08-29
EP1362601B1 (fr) 2007-01-03
US20040132783A1 (en) 2004-07-08
KR20030080013A (ko) 2003-10-10
EP1742052B1 (fr) 2008-10-29
JP4255285B2 (ja) 2009-04-15
AU2002233677B2 (en) 2005-01-06
DE60217300T2 (de) 2007-10-04
CN100384482C (zh) 2008-04-30

Similar Documents

Publication Publication Date Title
HK1099363A1 (en) Method for testing effect of angiogenesis inhibitor via integrin expression inhibition
EP1287839A3 (fr) Dispositif et méthode de mesure pour déterminer des paramètres de fluides médicaux
WO2003084382A3 (fr) Appareil et procede assurant la qualite des mesures d'impedance effectuees sur le sein d'une patiente
BR0315287A (pt) Método para determinar a exatidão de um sensor de pressão em um cassete cirúrgico
WO2004103145A3 (fr) Methode de verification de pre-traitement en radiotherapie
FI20000417A0 (fi) Ihmiseen liittyvä mittausarviointi
DE60124736D1 (de) Vorrichtung zur messung des abschnittsweisen volumens und der elektrischen parallelleitfähigkeit einer herzkammer oder eines blutgefässes
DE69920940D1 (de) Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
TW374131B (en) A data collection apparatus
WO2006056907A3 (fr) Systeme de detection de depression
WO2002027326A3 (fr) Procede et trousse pour la determination transdermique de la concentration d'une analyte dans le sang
EP1707953A4 (fr) Procede de mesure d'hematocrite (hct), detecteur utilise a cet effet, et instrument de mesure
ATE485764T1 (de) Vorrichtung zur schätzung des hämatokrits
CA2366682A1 (fr) Inhibiteur tissulaire de metalloproteinases matricielles type-1 (timp-1) comme marqueur de cancer
DE60035174D1 (de) Invasives verfahren zur in vivo analytvermessung
EP2117422A4 (fr) Procédé et système pour déterminer un état d'autorégulation cérébrovasculaire d'un patient
WO2008069881A3 (fr) Profilage d'expression génique pour l'identification, la surveillance et le traitement d'un mélanome
WO2002091910A3 (fr) Moniteur d'ecoulement sanguin pour le choc et la ressuscitation
SE0102919D0 (sv) Medical device
DE69533319D1 (de) Messung des schwellwertes bei atemfühlern
ATE446561T1 (de) Sensoranordnung
WO2004099756A3 (fr) Detecteur optique de substance sanguine a analyser corrige a zero
DE60307448D1 (de) Vorrichtung und verfahren zur messung der vaskulären impedanz
Kim et al. A comparison of the implant stability among various implant systems: clinical study
BR0314638A (pt) Equipamento de medição para medir dentaduras e diâmetros em componentes dinamicamente balançados

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140221